Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
暂无分享,去创建一个
B. Sikic | N. Bartlett | G. Fisher | B. Lum | N. Brophy | J. Halsey | M. N. Ehsan | M. Ehsan
[1] I. Roninson. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells , 2012, Springer US.
[2] P. Goodman,et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. , 1993, Cancer research.
[3] W. Dalton,et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] O. Fardel,et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. , 1993, Blood.
[5] B. Sikic,et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Sikic,et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Sonneveld,et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.
[8] V. Ling,et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. , 1991, The New England journal of medicine.
[9] A. Pourtier-Manzanedo,et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. , 1991, Cancer research.
[10] J. M. Ford,et al. Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.
[11] D. Kerr,et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. , 1990, British Journal of Cancer.
[12] V. Ling,et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Peter Veng-Pedersen,et al. Mean Time Parameters in Pharmacokinetics , 1989 .
[14] M. Ratain,et al. Pharmacokinetics and pharmacodynamics of long‐term continuous‐infusion doxorubicin , 1989, Clinical pharmacology and therapy.
[15] B. Kahan,et al. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. , 1988, Transplantation.
[16] G. T. Budd,et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Olson,et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[18] I. Pastan,et al. Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.
[19] Y. Ostchega,et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Gupta,et al. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.
[21] R. Ganapathi,et al. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. , 1983, Cancer research.
[22] W J Jusko,et al. LAGRAN program for area and moments in pharmacokinetic analysis. , 1983, Computer programs in biomedicine.
[23] M Lemaire,et al. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood , 1982, The Journal of pharmacy and pharmacology.
[24] T. Tsuruo,et al. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.
[25] J. Willson,et al. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. , 1980, Cancer research.
[26] S. Shapiro,et al. An Approximate Analysis of Variance Test for Normality , 1972 .
[27] M. Zemaitis,et al. The effects of cyclosporin A (CsA) on hepatic microsomal drug metabolism in the rat. , 1986, Drug metabolism and disposition: the biological fate of chemicals.